Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) was $14.42 for the day, up 2.05% from the previous closing price of $14.13. In other words, the price has increased by $2.05 from its previous closing price. On the day, 1.65 million shares were traded. RDY stock price reached its highest trading level at $14.45 during the session, while it also had its lowest trading level at $14.1812.
Ratios:
Our analysis of RDY’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.43 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 87.58. For the most recent quarter (mrq), Quick Ratio is recorded 1.36 and its Current Ratio is at 1.89. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.01.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RDY now has a Market Capitalization of 12210784256 and an Enterprise Value of -2345212416. As of this moment, Dr.’s Price-to-Earnings (P/E) ratio for their current fiscal year is 18.04, and their Forward P/E ratio for the next fiscal year is 22.63. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.06 while its Price-to-Book (P/B) ratio in mrq is 2.95. Its current Enterprise Value per Revenue stands at -0.007 whereas that against EBITDA is -0.026.
Stock Price History:
The Beta on a monthly basis for RDY is 0.32, which has changed by -0.12244403 over the last 52 weeks, in comparison to a change of 0.13054323 over the same period for the S&P500. Over the past 52 weeks, RDY has reached a high of $16.85, while it has fallen to a 52-week low of $12.26. The 50-Day Moving Average of the stock is -1.61%, while the 200-Day Moving Average is calculated to be 1.29%.
Shares Statistics:
RDY traded an average of 1.49M shares per day over the past three months and 1007290 shares per day over the past ten days. A total of 834.58M shares are outstanding, with a floating share count of 832.31M. Insiders hold about 0.00% of the company’s shares, while institutions hold 13.25% stake in the company. Shares short for RDY as of 1753920000 were 9892750 with a Short Ratio of 6.65, compared to 1751241600 on 10941723. Therefore, it implies a Short% of Shares Outstanding of 9892750 and a Short% of Float of 2.31.
Dividends & Splits
With its trailing 12-month dividend rate of 8.0, RDY has a forward annual dividend rate of 0.09. Against a Trailing Annual Dividend Yield of 0.5661713The stock’s 5-year Average Dividend Yield is 0.72. The current Payout Ratio is 8.90% for RDY, which recently paid a dividend on 2025-07-25 with an ex-dividend date of 2025-07-25. Stock splits for the company last occurred on 2024-11-05 when the company split stock in a 5:1 ratio.
Earnings Estimates
Analysts are recommending an EPS of between $68.43 and $68.43 for the fiscal current year, implying an average EPS of $68.43. EPS for the following year is $54.78, with 1.0 analysts recommending between $54.78 and $54.78.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $90.33B to a low estimate of $86.32B. As of the current estimate, Dr. Reddy’s Laboratories Ltd. ADR’s year-ago sales were $80.16BFor the next quarter, 4 analysts are estimating revenue of $84.87B. There is a high estimate of $89.02B for the next quarter, whereas the lowest estimate is $81.82B.
A total of 37 analysts have provided revenue estimates for RDY’s current fiscal year. The highest revenue estimate was $364.68B, while the lowest revenue estimate was $329.41B, resulting in an average revenue estimate of $344.21B. In the same quarter a year ago, actual revenue was $325.54BBased on 36 analysts’ estimates, the company’s revenue will be $349.16B in the next fiscal year. The high estimate is $385.09B and the low estimate is $325.4B.
